Marksans Pharma

June 1 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD- TO ACQUIRE 100% OF NETHERLANDS-BASED QLINIQ B.V

Source text: ID:nBSEcgQTnX

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS jump 15.6% to 254.7 rupees, their highest since July 2025

** Co's Q4 consol net profit rises 63.6% to 1.48 billion rupees ($15.5 million), rev from ops rises 20.8% to 8.56 billion rupees

** Co says rev growth led by strong recovery in co's UK revenue due to multiple product launches and improved order flow

** Adds price erosion in its UK products stabilised during the quarter

** Trading vols at 13x the 30-day average

** YTD, stock up ~38%

($1 = 95.4475 Indian rupees)

(Reporting by Mridula Kumar in Bengaluru)

(([email protected];))

April 1 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD - RECEIVES USFDA APPROVAL FOR BENZONATATE CAPSULES USP, 100 MG & 200 MG

• MARKSANS PHARMA LTD - RECEIVES USFDA APPROVAL FOR BENZONATATE CAPSULES

Source text: ID:nBSE1ZdcH9

Further company coverage: MARK.NS

(([email protected];))

Feb 5 (Reuters) - Marksans Pharma Ltd MARK.NS:

• DEC-QUARTER CONSOL NET PROFIT 1.13 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 7.54 BILLION RUPEES

Source text: [ID:]

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS rise 2% to 192 rupees, snapping a two-day losing streak

** Pharma co's UK unit gets approval to market its product Cetirizine

** More than 570,400 shares change hands by 1:35 pm IST vs 30-day avg of 1.4 mln shares

** YTD, however, MARK is down 35%

(Reporting by Komal Salecha)

(([email protected];))

** Shares of Marksans Pharma MARK.NS rise 3.2% to 184 rupees, mark their biggest intraday pct gain since July 30

** Stock set to snap a seven-session losing streak, if gains hold

** The pharma co's unit gets marketing authorization from the UK MHRA for 3 metformin hydrochloride products

** Marksans stock down 38%, YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

** Marksans Pharma MARK.NS slumps 10% to four-month low of 189 rupees; set for sixth consecutive session of losses

** Stock on course for biggest daily pct drop since April 4

** Co's Q1 consolidated profit falls 34% on higher costs

** Around 3 million shares change hands so far, about 2.3x 30-day avg volume

** YTD, MARK down 36.3%

(Reporting by Vivek Kumar M)

(([email protected];))

July 25 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD - BOARD RE-APPOINTS MARK SALDANHA AS MANAGING DIRECTOR

Source text: ID:nNSE5JHnbw

Further company coverage: MARK.NS

(([email protected];))

** India's Marksans Pharma MARK.NS gains 3.1% to 260.60 rupees

** US FDA finishes inspection at drugmaker's manufacturing facility in New York with no observations

** MARK also gets establishment inspection report from US FDA - showing successful completion of inspection

** Stock trims YTD losses to 12%

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Marksans Pharma MARK.NS rise as much as 2.3% to 256 rupees

** Stock on track to snap five-day losing streak
** Pharma co's UK unit gets marketing authorisation from regulator for oxybutynin hydrochloride oral solution to treat overactive bladder symptoms
** MARK last up 1%, cutting YTD losses to 15.7%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** India's Marksans Pharma MARK.NS rises 5%

** Co says Goa facility gets Australian nod for exports

** Stock set for third consecutive session of gains

** More than 1.7 mln shares change hands, 1.2x of 30-day avg

** Stock cuts YTD loss to ~27%

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Marksans Pharma MARK.NS rise 2.6% to 208.02 rupees apiece

** Generic drug formulations maker's UK unit gets marketing authorisation for Baclofen 10 mg tablets from country's drug regulator

** Baclofen used to treat muscle spasms

** MARK shares are down 30% in 2025 so far compared to the 3.1% drop in benchmark Nifty 50 .NSEI and 9.9% fall in pharma index .NIPHARM, according to exchange data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD- UK UNIT GETS MARKETING AUTHORIZATION FOR PRODUCT IBUPROFEN AND PARACETAMOL

Source text: [ID:]

Further company coverage: MARK.NS

Feb 11 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 1.05 BILLION RUPEES

• MARKSANS PHARMA DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.82 BILLION RUPEES

Source text: ID:nBSE7GJBDX

Further company coverage: MARK.NS

(([email protected];))

Nov 22 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA - USFDA APPROVAL FOR LORATADINE USP 10MG TABLETS

Source text: [ID:]

Further company coverage: MARK.NS

(([email protected];))

Nov 12 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA SEPT-QUARTER CONSOL NET PROFIT 967.2 MILLION RUPEES

• MARKSANS PHARMA SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 6.42 BILLION RUPEES

Source text: ID:nNSE1WZ3QZ

Further company coverage: MARK.NS

(([email protected];;))

Aug 21 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD - UNIT RELONCHEM RECEIVES MARKETING AUTHORIZATION FOR ITS PRODUCTS

• MARKSANS PHARMA - UNIT GETS MARKETING AUTHORIZATION FOR FLUOXETINE 10MG, 30MG, 60MG CAPSULES

Source text for Eikon: [ID:]

Further company coverage: MARK.NS

(([email protected];;))

** Shares of Marksans Pharma MARK.NS turn positive after drugmaker says U.S. FDA closed inspection at its Goa facility

** Shares last up 0.7% at 221.70 rupees; were down 1.4% before news

** Co says FDA classified its Goa unit as "voluntary action indicated" after inspection

** VAI indicates objectionable conditions or practices were found, but the agency won't recommend any administrative or regulatory action, FDA's website said

** MARK's 37% rise this year compared to ~33% rise in pharma stocks .NIPHARM

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of Marksans Pharma MARK.NS up 9.4% at 205.4 rupees, its steepest gain since July 24

** Pharmaceutical formulations maker's Q1 consol net profit grew ~30%, rev up 18%

** Shares see busiest day in about 3 weeks, with over 3.2 mln shares traded

** Stock up 28% YTD, vs an 81% and 9% rise in peers Natco Pharma NATP.NS and Mankind Pharma MNKI.NS, respectively

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Aug 13 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD JUNE-QUARTER CONSOL NET PROFIT 887.5 MILLION RUPEES

• MARKSANS PHARMA LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 5.91 BILLION RUPEES

Source text for Eikon: ID:nBSEbkbfV1

Further company coverage: MARK.NS

(([email protected];))

July 2 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA LTD - UNIT RELONCHEM GETS MARKETING AUTHORIZATION FROM UKMHRA

Source text for Eikon: ID:nBSE2bS85Q

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS slide 11.4%

** Stock set for biggest one-day drop since March 2020

** Drugmaker posts 4.5% Y/Y fall in Q4 profit

** Rev rises 15.2%, but is outpaced by costs jumping 21.3%

** Stock reverses course to YTD losses; now down ~5% YTD

** Stock had surged ~177% in 2023, its best year since 2020

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected]))

** Shares of Marksans Pharma MARK.NS rose as much as 2.8%; last up 0.9% to 166.2 rupees

** Co's unit got marketing authorisation from UK drug regulator for Levetiracetam Relonchem 100 mg/mL oral solution used in seizure treatment

** Stock on track for second straight monthly climb, up 1.5% in May after falling for four straight months through March

** Stock up ~3% YTD vs ~13% climb in Nifty Pharma index .NIPHARM, of which MARK is not a member

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

April 18 (Reuters) - Marksans Pharma Ltd MARK.NS:

• USFDA INSPECTION AT COMPANY'S MANUFACTURING FACILITY IN VERNA, GOA, INDIA

• COMPANY HAS RECEIVED 5 INSPECTIONAL OBSERVATIONS IN FORM 483

• THERE IS NO DATA INTEGRITY OBSERVATION

Further company coverage: MARK.NS

(([email protected];))

Feb 13 (Reuters) - Marksans Pharma Ltd MARK.NS:

• MARKSANS PHARMA DEC-QUARTER CONSOL NET PROFIT 832.4 MILLION RUPEES VERSUS 634.1 MILLION RUPEES

• MARKSANS PHARMA LTD DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.86 BILLION RUPEES VERSUS 4.8 BILLION RUPEES

Source text for Eikon: ID:nNSE9j7rXt

Further company coverage: MARK.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS rise as much as 10.5% to hit a record high of 128.50 rupees

** Stock marks sharpest intraday pct gain since July 26

** The drugmaker reported a 36.3% Y/Y rise in Q2 consolidated net profit while rev from ops rose 17.3% Y/Y

** EBITDA in Q2 grew by 41.9% with an EBITDA margin of 21.4%

** Operating margins expanded, compared with prior year, and sequentially led by reduced raw material pricing and freight cost, said MD and CEO Mark Saldanha

** Stock is witnessing its most active trading session since July 12, with more than 14.3 mln shares change hands, 8x of 30-day avg

** Marksans stock up ~120% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Marksans Pharma MARK.NS rise as much as 3.6% to 116.65 rupees apiece

** Drug maker's unit receives marketing authorisation from United Kingdom for Cyanocobalamin tablets

** Drug used to treat Vitamin B12 deficiencies and anaemia

** Trading volume is 2.87 mln shares as of 1:13 p.m. IST, nearly twice the 30-day avg - LSEG data

** Including day's gains, MARK up 99% in 2023 so far

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Nov 3 (Reuters) - Marksans Pharma Ltd MARK.NS:

• TIME-CAP LABORATORIES, INC, RECEIVES ESTABLISHMENT INSPECTION REPORT FROM US FDA

• NO 483' S WERE ISSUED DURING THE AUDIT

Source text for Eikon: ID:nNSE3Ymvl2

Further company coverage: MARK.NS

(([email protected];;))

Nov 1 (Reuters) - Marksans Pharma Ltd MARK.NS:

• CO'S MANUFACTURING FACILITY HAS UNDERGONE INSPECTION FROM GERMAN HEALTH AUTHORITIES

• AUTHORITIES HAVE NOT FOUND ANY CRITICAL OR MAJOR OBSERVATIONS

Source text for Eikon: ID:nNSE1MPrh0

Further company coverage: MARK.NS

(([email protected];))

Oct 3 (Reuters) - Marksans Pharma Ltd MARK.NS:

• US FDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES USP, 20 MG (OTC)

Further company coverage: MARK.NS

(([email protected];))